logo-loader
viewWPP PLC

WPP reaffirms 2019 guidance although first-quarter like-for-like sales drop due to "significant" US client losses

The FTSE 100-listed firm saw its reported revenue increase by 0.9% year-on-year to £3.59bn in the first quarter of 2019, but like-for-like revenue fell 1.3%

WPP sign
WPP said North America was its weakest performing region, with like-for-like sales there down 8.5%

WPP PLC (LON:WPP) reaffirmed its 2019 guidance as the advertising giant posted a rise in headline first-quarter revenue but saw like-for-like sales drop due to "significant" US client losses.

The FTSE 100-listed firm saw its reported revenue increase by 0.9% year-on-year to £3.59bn in the first quarter of 2019, but like-for-like revenue fell 1.3%.

READ: WPP shares jump as new boss unveils fresh strategy to turn around business

The company – which last year saw its founder and chief executive Martin Sorrell depart under a cloud - said North America was its weakest performing region, with like-for-like sales there down 8.5%.

It pointed out that that while disappointing, the performance was in line with its budgets and actions it has taken since September with its creative and healthcare agencies, alongside leadership changes, are intended to address its US performance.

In the UK, WPP said like-for-like revenue was down 0.9%, which was a slight decline on 2018's performance.

Mark Read, WPP’s new chief executive – who took up his post in September 3018 - said: "As anticipated, our first quarter trading update reflects the impact of certain significant client losses in 2018, in particular in the United States.

“Although we face a challenging year, especially in the first half, I am encouraged by how well our people, agencies and clients are responding to our new strategic direction. Our expectations for the full year are unchanged."

In early morning trading, shares in WPP were down 0.7% at 899.40.

Quick facts: WPP PLC

Price: 967.4 GBX

LSE:WPP
Market: LSE
Market Cap: £12.21 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Summit Therapeutics' Glyn Edwards talks US$50mln backing and ridinilazole...

Summit Therapeutics PLC's (LON:SUMM, NASDAQ:SMMT) CEO Glyn Edwards sat down with Proactive London's Andrew Scott following the news of a US$50mln funding deal with biotech billionaire Bob Duggan. The investment will help get the company’s next-generation antibiotic through phase III clinical...

8 hours, 31 minutes ago

2 min read